# A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

> **NCT06113731** · PHASE2 · UNKNOWN · sponsor: **CNBG-Virogin Biotech (Shanghai) Ltd.** · enrollment: 980 (estimated)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** COVID-19 mRNA Vaccine (ZSVG-02-O)
- **BIOLOGICAL:** COVID-19 mRNA Vaccine (ZSVG-02-O)
- **BIOLOGICAL:** COVID-19 Vaccine (Vero Cell) ,Inactivated

## Key facts

- **NCT ID:** NCT06113731
- **Lead sponsor:** CNBG-Virogin Biotech (Shanghai) Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-10
- **Primary completion:** 2023-10-30
- **Final completion:** 2024-10
- **Target enrollment:** 980 (ESTIMATED)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06113731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06113731, "A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06113731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*